The effect of vitamin D in the treatment of heart failure

The effect of vitamin D3 supplementation on serum levels of B type natriuretic peptide , tumor necrosis factor alpha , high sensitivity c-reactive protein and 6 minute walk distance test in stage ? systolic heart failure patients with vitamin D deficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016102113678N13

Enrollment

Registered

2017-03-02

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure. Cardiac, heart or myocardial failure NOS

Interventions

Intervention 1: Viatmin D3 tablet (50000 International Unit) once a week , for two months. Intervention 2: placebo tablet , once a week , for two months.

Treatment - Drugs

Placebo

Viatmin D3 tablet (50000 International Unit) once a week , for two months

placebo tablet , once a week , for two months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria : class 3 of the New York Heart Association Classification(NYHA); ejection fraction less than 50% ; treated with heart failure medications in the last 3 months ; the level of vitamin D less than 20 ng/ml. Exclusion criteria : vitamin D reception in the last 2 months ; acute gastrointestinal problems ;using interacting drugs with the homeostasis of vitamin D such as Corticosteroids , Thyroxine , anti-epileptic drugs, Tetracycline, Ketoconazole, Cholestyramine, Phenobarbital and Phenytoin ; bone fractures ; continuous consumption of cigarettes; kidney disease ; malignancies ; need to change the type and amount of drugs during the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
B type natriuretic peptide. Timepoint: before and after intervention. Method of measurement: ELISA.;High sensitivity C-reactive protein. Timepoint: before and after intervention. Method of measurement: ELISA.;Tumor necrosis factor alpha. Timepoint: before and after intervention. Method of measurement: ELISA.;Vitamin D. Timepoint: before and after intervention. Method of measurement: ELISA.;6 minute walk distance test. Timepoint: before and after intervention. Method of measurement: walking distance (meter).	—

Measure

Time frame

B type natriuretic peptide. Timepoint: before and after intervention. Method of measurement: ELISA.;High sensitivity C-reactive protein. Timepoint: before and after intervention. Method of measurement: ELISA.;Tumor necrosis factor alpha. Timepoint: before and after intervention. Method of measurement: ELISA.;Vitamin D. Timepoint: before and after intervention. Method of measurement: ELISA.;6 minute walk distance test. Timepoint: before and after intervention. Method of measurement: walking distance (meter).

—

Secondary

Measure	Time frame
Systolic blood pressure. Timepoint: before and after intervention. Method of measurement: manometer.;Diastolic blood pressure. Timepoint: before and after intervention. Method of measurement: manometer.;Weight. Timepoint: before and after intervention. Method of measurement: scale.;Body mass index. Timepoint: before and after intervention. Method of measurement: with BMI formula.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 19, 2026